Therefore, to discover other potential treatment options for targeted therapy-resistant melanoma patients, we investigated communication mechanisms possibly mediating the protective effect of TTR macrophages on drug-exposed malignant cells. In human patients, TTR but not TTS or other macrophages expressed high levels of the secreted factor SPP1 that was predicted to signal to CD44+ malignant cells. The gene discussed is SPP1; the disease is melanoma.